| ¿µ¹® | hypertension | ÇÑ±Û | °íÇ÷¾Ð |
|---|---|---|---|
| ¼³¸í | µ¿¸ÆÀÇ Ç÷¾ÐÀÌ ³ôÀº °Í. ÀϹÝÀûÀ¸·Î ¸»ÇÏ´Â °íÇ÷¾ÐÀº ÀÌ µ¿¸Æ¼º °íÇ÷¾ÐÀ» ¸»ÇÑ´Ù. Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÏ´Â °ÍÀ¸·Î ´ë°³ ƯÀÌÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð°ú À̿ϱâÇ÷¾ÐÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ ¶§ÀÇ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ 120/80À̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù. °íÇ÷¾ÐÀº ÁÖ·Î À̿ϱâÀÇ Ç÷¾ÐÀ» ±âÁØÀ¸·Î Á¤ÇÑ´Ù. ¿©·¯ °¡Áö ±âÁØÀÌ ÀÖÀ¸³ª À̿ϱâ Ç÷¾ÐÀÌ 90mmHgÀÌ»óÀÎ °æ¿ì¸¦ ¸»ÇÑ´Ù. °íÇ÷¾Ð ÀÚü¿¡ ÀÇÇÑ Áõ»óÀº º°·Î ¾ø´Ù. ´Ù¸¸ °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´Áõ°ú µ¿¸Æ°æÈÀÇ ÃËÁø¿¡ ÀÇÇØ º´¹ßÇÏ´Â Áúȯ¿¡ ÀÇÇÏ¿© Áõ»óÀÌ »ý±ä´Ù. °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´ÁõÀº ´ë°³ Ç÷°ü¿¡ °É¸®´Â °úµµÇÑ ¾Ð·ÂÀ¸·Î ÀÎÇÑ Ç÷°üÀÇ ¼Õ»óÀÌ Áß¿äÇÑ ¿øÀÎÀÌ´Ù. °íÇ÷¾ÐÀº µ¿¸Æ°æÈÀÇ ÁÖ¿ä À¯¹ßÀÎÀÚ ÁßÀÇ ÇϳªÀÌ´Ù. µ¿¸Æ°æÈ´Â µ¿¸ÆÀÇ º®ÀÌ µÎÅÍ¿öÁö°í µ¿¸ÆÀÌ Åº·ÂÀ» ÀÒ¾î¹ö¸®´Â ÁúȯÀÌ´Ù. ¾î¶² µ¿¸ÆÀÌ µ¿¸Æ°æÈ¿¡ °É¸®¸é ÀÌ µ¿¸ÆÀº µÎÅÍ¿öÁø Ç÷°üº®¿¡ ÀÇÇØ¼ ³»°æÀÌ ÀÛ¾ÆÁö°Ô µÈ´Ù. ÀÌ·¸°Ô µÇ¸é ±× µ¿¸ÆÀ¸·ÎºÎÅÍ Ç÷¾×À» °ø±Þ¹Þ´ø Àå±â´Â Ç÷¾×À» Àû°Ô °ø±Þ¹Þ°Ô µÇ°í ±× Á¤µµ°¡ ½ÉÇÏ°Ô µÇ¸é ±× Àå±â´Â °á±¹ ¼Õ»óÀ» ÀÔ°Ô µÈ´Ù. µ¿¸Æ°æÈ·Î ÀÎÇÑ Áúº´ÀÇ ´ëÇ¥ÀûÀÎ ¿¹´Â ½ÉÀåÀÇ ±ÙÀ°¿¡ Ç÷¾×À» °ø±ÞÇÏ´Â ½ÉÀ嵿¸Æ¿¡ µ¿¸Æ°æÈÀÇ º¯È°¡ ¿À´Â ½ÉÀ嵿¸Æº´ÀÌ´Ù. °íÇ÷¾ÐÀÇ Ä¡·á¿¡ ¾²ÀÌ´Â ¾à¹°Àº ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù. -ÀÌ´¢Á¦-ÄáÆÏ¿¡¼ ¼öºÐ°ú ÀüÇØÁúÀÇ ¹èÃâÀ» ÃËÁø½ÃŰ´Â ¾à¹°. ü³»ÀÇ ¼öºÐÀÇ ¾çÀ» °¨¼Ò½ÃÄѼ Ç÷¾×ÀÇ È帣´Â ¾çÀ» Àû°ÔÇÏ°í ¶Ç Ç÷°üÁÖÀ§ Á¶Á÷ÀÇ ¼öºÐÀÇ °¨¼Ò·Î Ç÷°üÀ» È®Àå½ÃŰ´Â ¿ªÇÒ(Ç÷°üÀÌ ÀÖ°í ±× Ç÷°üÀ» ½×°í ÀÖ´Â Á¶Á÷¿¡ ¼öºÐÀÌ Â÷ ÀÖÀ¸¸é ±× Á¶Á÷ÀÌ Ç÷°üÀ» ´·¯¼ Ç÷°üÀÌ È®ÀåÇÏ´Â °ÍÀ» ¹æÇØÇÑ´Ù)·Î Ç÷¾ÐÀ» °¨¼Ò½ÃŲ´Ù. -Ä®½·-Åë·ÎÂ÷´ÜÁ¦£¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Áï Ç÷°üÀÇ ¼öÃà¿¡ °ü¿©ÇÏ´Â Ç÷°üµµ ¿ª½Ã ¼öÃàÀ» À§Çؼ´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Ä®½·-Åë·ÎÂ÷´ÜÁ¦´Â ±ÙÀ°¼¼Æ÷ ¼ÓÀ¸·Î Ä®½·ÀÌ µé¾î°¡´Â °ÍÀ» ¹æÁöÇØ¼ Ç÷°ü±ÙÀ°ÀÇ ¼öÃàÀ» ¹æÇØÇϰí ÀÌ·Î ÀÎÇØ¼ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÑ´Ù. -¾ËÆÄÂ÷´ÜÁ¦, º£Å¸Â÷´ÜÁ¦-Ç÷°üÀº ÀÚÀ²½Å°æ°èÀÇ Áö¹è¸¦ ¹Þ´Â´Ù. ±×Áß¿¡¼µµ Ç÷°üÀº ±³°¨½Å°æÀÇ ¿µÇâ¿¡ ÀÇÇØ¼ ¼öÃà°ú ÀÌ¿ÏÀ» ÇÑ´Ù. ±³°¨½Å°æÀÇ ÀÛ¿ëÀº ±× ¼ö¿ëü¿¡ µû¶ó ´Þ¶óÁø´Ù. ±³°¨½Å°æÀÇ ¼ö¿ëüÀÇ Á¾·ù¿¡´Â ¾ËÆÄ¼ö¿ëü¿Í º£Å¸¼ö¿ëü°¡ ÀÖ´Ù. Ç÷°üÀ» Áö¹èÇϰí ÀÖ´Â ±³°¨½Å°æ¿¡¼ ¾ËÆÄ¼ö¿ëü´Â Ç÷°üÀÇ ¼öÃàÀ» ÀÏÀ¸Å°°í º£Å¸¼ö¿ëü´Â Ç÷°üÀÇ È®ÀåÀ» ÀÏÀ¸Å²´Ù. ±×·¯¹Ç·Î ¾ËÆÄ¼ö¿ëüÀÇ ÀÛ¿ëÀ» ¸·´Â °æ¿ì¿¡ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÒ ¼ö ÀÖ°í º£Å¸-¼ö¿ëüÀÇ ÀÛ¿ëÀ» Ç×Áø½Ãų °æ¿ì¿¡ ¿ª½Ã Ç÷°üÀÇ È®Á¤À» À¯µµÇÒ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | renal hypertension | ÇÑ±Û | ÄáÆÏ¼º°íÇ÷¾Ð |
|---|---|---|---|
| ¼³¸í | ÄáÆÏ½ÇÁúÀÇ º´º¯À¸·Î ÀÎÇØ ¾ß±âµÈ °íÇ÷¾Ð. ÄáÆÏÀÇ ´ëÇ¥Àû ±â´ÉÀº ³ëÆó¹° ¹× ¼öºÐÀÇ ¹è¼³ÀÌ´Ù. ±×·±µ¥ ÀÌ·¯ÇÑ ÄáÆÏ±â´É¿¡ ÀÌ»óÀÌ »ý°åÀ» °æ¿ì ü³»¿¡ °úÀ×¼öºÐÀÇ ÃàÀûÀÌ ¹ß»ýÇÏ°Ô µÈ´Ù. À̿Ͱ°Àº °úÀ×¼öºÐÀÇ ÃàÀûÀº Ç÷°ü³» Á¤¼ö¾ÐÀ» »ó½Â½ÃÄÑ °íÇ÷¾ÐÀ» À¯¹ßÇÏ°Ô µÈ´Ù. Ä¡·á´Â ¿øÀÎ ÄáÆÏº´ÀÇ ±³Á¤À̸ç ÀÌÀ¯¸¦ ¸ð¸£´Â ¿ø¹ß°íÇ÷¾Ð°ú ´Þ¸® ÄáÆÏ¼º°íÇ÷¾ÐÀÇ °æ¿ì¿¡´Â ¿øÀÎ ÄáÆÏº´ÀÌ ±³Á¤µÇ¸é °íÇ÷¾Ðµµ »ç¶óÁö°Ô µÈ´Ù. |
||
| LP | labile peptide; labile protein; laboratory procedure; lactic peroxidase; lamina propria; laryngophar... |
|---|---|
| JVP | [POMD P 49 - 52] 1) Jugular Vein Pressure 2) Jugular Venous Pulse ... |
| IPH | idiopathic portal hypertension; idiopathic pulmonary hemosiderosis; idiopathic pulmonary hypertensio... |
| PHT | phenytoin; portal hypertension; primary hyperthyroidism; pulmonary hypertension |
| PPH | past pertinent history; persistent pulmonary hypertension; phosphopyruvate hydratase; postpartum hem... |
| STOP Hypertension | Swedish Trial in Old Patients with Hypertension |
|---|---|
| LT | Heat-labile |
| LT | Heat-labile enterotoxin |
| LT | Heat-labile toxin |
| LT | Labile Toxin |
| labile hypertension | Frequently changing levels of elevated blood pressure. (05 Mar 2000) |
|---|
| plasma labile factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
|---|---|
| heat-labile | Destroyed or altered by heat. (05 Mar 2000) |
| labile | 1. Gliding, moving from point to point over the surface, unstable, fluctuating. 2. <chemistry> Chemically unstable. Origin: L. Labilis = unstable, from labi = to glide (18 Nov 1997) |
| labile affect | The rapid shifts in outward emotional expressions; often associated with organic brain syndromes such as intoxication. (05 Mar 2000) |
| labile current | An electrical current applied to the body by means of electrodes that are constantly shifted about. (05 Mar 2000) |
| labile elements | Tissue cells, as of epithelium, connective tissue, etc., that continue to multiply by mitosis during the life of the individual. (05 Mar 2000) |
| labile factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| labile pulse | Frequent changes in pulse rate. (05 Mar 2000) |
| accelerated hypertension | <cardiology> A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure. Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension. (27 Sep 1997) |
| adrenal hypertension | Hypertension due to an adrenal medullary pheochromocytoma or to hyperactivity or functioning tumour of the adrenal cortex. (05 Mar 2000) |
| benign hypertension | Hypertension that runs a relatively long and symptomless course. (05 Mar 2000) |
| borderline hypertension | By consensus, that blood pressure zone between highest acceptable "normal" blood pressure and hypertensive blood pressure. The Framingham Heart Study defines this as pressures between 140 and 160 mm Hg systolic and 90 and 95 mm Hg diastolic. (05 Mar 2000) |
| pale hypertension | Hypertension with pallor of the skin, a severe form with pronounced constriction of peripheral vessels. (05 Mar 2000) |
| malignant hypertension | A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure. Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension. (27 Sep 1997) |
| renal hypertension | Hypertension secondary to renal disease. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|